Bristol Myers Squibb (CELG-RI) Assets Average (2009 - 2026)
Bristol Myers Squibb (CELG-RI) posted quarterly Assets Average of $87.1 billion for Q2 2026, down 6.94% year-over-year from $93.6 billion in Q2 2025, and down 1.36% quarter-over-quarter from $88.3 billion in Q1 2026.
Bristol Myers Squibb (CELG-RI) Assets Average (2009 - 2026) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has reported Assets Average for 17 consecutive years, with $87.1 billion the latest figure, recorded in Q2 2026.
- In Q2 2026, Assets Average fell 6.94% year-over-year to $87.1 billion; the TTM figure through Jun 2026 stood at $87.1 billion (down 6.94% YoY), while the FY2025 annual figure was $91.3 billion, down 2.73% from the prior year.
- Assets Average slipped to $87.1 billion in Q2 2026 per CELG-RI's latest filing, from $88.3 billion in the prior quarter.
- Across five years, Assets Average topped out at $106.2 billion in Q1 2022 and bottomed at $87.1 billion in Q2 2026.
- Historically, Assets Average has averaged $95.1 billion across 5 years, with a median of $94.0 billion in 2023.
- Annual changes were most pronounced in 2022 — Assets Average decreased 11.44% — and 2024, when it climbed 3.15%.
- Bristol Myers Squibb's Assets Average stood at $97.5 billion in 2022, then decreased by 4.41% to $93.2 billion in 2023, then retreated by 0.08% to $93.1 billion in 2024, then increased by 0.35% to $93.5 billion in 2025, then dropped by 6.86% to $87.1 billion in 2026.
- Business Quant data shows CELG-RI's Assets Average at $87.1 billion in Q2 2026, $88.3 billion in Q1 2026, and $93.5 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 200.98 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 135.79 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 129.24 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 114.92 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 94.07 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 52.82 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 204.57 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | 83.80 Bn |
| 10 | Bristol Myers Squibb | 188.27 Mn | -10.88 Bn | 9.25 Bn | 87.06 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 87.06 Bn |
| Mar 31, 2026 | 88.26 Bn |
| Dec 31, 2025 | 93.46 Bn |
| Sep 30, 2025 | 95.78 Bn |
| Jun 30, 2025 | 93.55 Bn |
| Mar 31, 2025 | 92.52 Bn |
| Dec 31, 2024 | 93.14 Bn |
| Sep 30, 2024 | 94.16 Bn |
| Jun 30, 2024 | 96.84 Bn |
| Mar 31, 2024 | 97.10 Bn |
| Dec 31, 2023 | 93.21 Bn |
| Sep 30, 2023 | 92.38 Bn |
| Jun 30, 2023 | 93.89 Bn |
| Mar 31, 2023 | 95.55 Bn |
| Dec 31, 2022 | 97.51 Bn |
| Sep 30, 2022 | 99.28 Bn |
| Jun 30, 2022 | 101.70 Bn |
| Mar 31, 2022 | 106.17 Bn |
| Dec 31, 2021 | 110.10 Bn |
| Sep 30, 2021 | 110.85 Bn |